Prescription Drug Labeling Conference

Published: 5-Oct-2017

The goal of this interactive conference is to provide helpful information pertinent to prescription drug labeling development. FDA and industry labelling specialists will present their unique perspectives concerning approaches and challenges in developing the prescribing information, patient labelling and structured product labelling (SPL).

Meeting participants will have an opportunity to share their experiences and ask questions during the question and answer panels.

Event venue: Tommy Douglas Conference Center

Organiser: Center for Drug Evaluation and Research Small Business and Industry Assistance (CDER SBIA)

Email: info@sbiaevents.com

Web: Register for the event

Trending Articles

  1. ASGCT Annual Meeting 2024 7-11 May, 2024 | Meeting | Portland, OR
  2. CPhI North America 7-9 May 2024 | Exhibition | Pennsylvania, US
  3. Cleanroom Conference UK 22–23 May 2024 | Exhibition | Birmingham, UK
  4. CPhI Worldwide 2011 <b>25 - 27 October 2011</b><br> Messe Frankfurt
  5. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany

You may also like

Manufacturing

What's in an FDA approval? How a start-up company gets its drug to market

The FDA wields a supreme amount of power in the regulatory realm of the pharmaceutical industry. For smaller start-ups or those newer to the industry, navigating the compliance pathways can prove a daunting task
Regulatory

FDA grants landmark approval for Alzheimer’s treatment

LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
Regulatory

Sequana submits IND application for heart failure treatment

The IND application includes data from the previously reported GLP animal and Phase 1 CHIHUAHUA studies
Regulatory

FDA grants marketing approval for safety syringes

Zephyrus' needle system contains an internal mechanism that retracts the needle inside the syringe after activation
Regulatory

FDA releases final guidance for upcoming biological product transition

The BPCI Act requires that a marketing application for a “biological product” must be submitted as a biologics license application
Personal Protection

Coronavirus: Emergency planning for the drug supply chain

The FDA has outlined its expectations and actions regarding supply chain and inspections in China
Regulatory

FDA swears in Dr Stephen Hahn as new Commissioner

Oncolgy specilalist Dr Stephen Hahn has started his new position as leader of the US regulatory body
Subscribe now